Analysis Of Tigecycline Research Articles

A Review on Analytical Methods for Tigecycline Estimation from Its Bulk and Dosage Form.

Tigecycline (TIG) is a third-generation glycylcycline derivative used as an antimicrobial and anticancer agent for the past few years. Its intricate structure makes it more vulnerable towards degradation under the influence of various environmental factors and leads to the generation of impurities. Due to its stability issues, TIG is available as a lyophilized powder for injection. The analysis of TIG becomes a cumbersome task for the analysts due to its instability in solution form. As TIG works as a life-saving drug, it's important to review its analytical methods for its quality control. The present review discusses various analytical methodologies for determining TIG from its bulk, lyophilised powder, and pharmacopeial methods for determining its impurities. Further, the factors responsible for the instability of TIG are briefly mentioned, along with its physicochemical properties. Numerous alternative analytical techniques such as UV-visible spectrophotometry, spectrofluorimetric methods, RP-HPLC (Reversed-Phase High-Performance Liquid Chromatography) and FT-IR (Fourier Transform Infra-Red), electrophoresis has been reported for quantification, identification and characterisation of TIG. Several analytical techniques are available to be used as a quality control tool for tigecycline, including HPLC without derivatisation, whereas the fluorescence technique requires derivatisation using acidic dye. Few methods require tedious pre-sample preparation techniques; become time-consuming, and involve using one or more organic solvents, there is a need to develop eco-friendlier methods for analysing tigecycline.

Analysis of tigecycline in the cerebrospinal fluidand serum of patients with Acinetobacter baumannii central nervous system infection.

Aim: This study aimed to establish a method to determine tigecycline (TGC) in the cerebrospinal fluid (CSF) and serum of 12 patients with multidrug-resistant Acinetobacter baumannii (MDRAB) central nervous system infection (CNSI) and evaluate the correlation of TGC in CSF and serum samples. Materials & methods: TGC in CSF and serum was detected by high-performanceliquid chromatography with tandem mass spectrometry. Results: In all12 patients, the CSF-to-serum ratio of TGC at asteady-state trough concentration ranged from 21.46to 44.46%, and the mean value was 31.61±8.13%. The correlation of TGC in CSF and serum was 0.5065. Conclusion: CNSI might have no potential to increase the penetration ability of TGC into theCSF. The correlation between the concentrations of TGC in CSF and serum at steady state was demonstrated to be positive.

Development of a monoclonal antibody-based immunochromatographic strip for the rapid detection of tigecycline in human serum.

In this study, a gold labelled immunochromatographic assay was developed to detect tigecycline (TGC) in human serum. For this purpose, an anti-TGC monoclonal antibody, 2G7, was produced and characterized, and was found to have a 50%-inhibitory concentration (IC50) of 2.303 ng mL-1 and a limit of detection (LOD) of 0.215 ng mL-1 for TGC. This strip assay had a visual limit of detection (vLOD) of 50 ng mL-1 and a cut-off value of 1000 ng mL-1 for TGC in human serum, when assessed by eye. With the aid of a strip scan reader, a quantitative determination of TGC was obtained with a calculated limit of detection (cLOD) of 15.03 ng mL-1. Analysis of TGC in human serum indicated that the results of our strip assay compared well with results obtained using ic-ELISA and LC-MS/MS. Therefore, this strip assay represents a sensitive and reliable method for the on-site detection of TGC in serum samples.

Analysis of Tigecycline's clinical use from a medical center in Taiwan

Analysis of Tigecycline's clinical use from a medical center in Taiwan

Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation

The number of reported cases of resistance to tigecycline is increasing. The aim of this study was to evaluate the current standard tigecycline dosage regimen from a pharmacokinetic/pharmacodynamic (PK/PD) perspective. Pharmacokinetic parameters and microbiological data were analyzed by Monte Carlo simulation in an evaluation of effectiveness. Tigecycline exhibits excellent in vitro antimicrobial activity, however the standard tigecycline dosing regimen fails to achieve the best outcome in vivo for the common drug-resistant strains, including Acinetobacter baumannii, Enterobacter spp, and Klebsiella pneumoniae. This may result in a lack of response to tigecycline therapy or to a further increase in the resistance rate. In the absence of new drugs on the horizon, rather than using a single fixed dosing regimen, tigecycline dosing needs to be optimized in order to achieve the desired successful clinical response and to prevent an escalation in drug resistance.